First-Line Mesothelioma Treatment in 2026: How to Choose Between Nivolumab+Ipilimumab and Pembrolizumab+Chemo

The treatment conversation for newly diagnosed unresectable pleural mesothelioma is no longer a single recommendation. As of late 2024, oncology teams have two FDA-approved first-line regimens that both demonstrated overall survival benefit in randomized phase 3 trials, and the choice between them is a real decision rather than a formality.

This guide is for someone who has just been told the disease is not surgically resectable and wants to walk into the next oncology appointment understanding what each option is. It draws on the primary trial publications, the FDA approval documents, and the National Cancer Institute’s current treatment summary. It does not rank one regimen as universally better than the other. The trial data does not support that ranking, and the decision is patient-specific.

The Two Approved First-Line Regimens

Both options replaced the longstanding standard of pemetrexed plus a platinum agent (cisplatin or carboplatin), which was established as the chemotherapy backbone by Vogelzang and colleagues in 2003. The two new regimens are:

Nivolumab plus ipilimumab. This is dual immune checkpoint inhibition. Nivolumab blocks PD-1 and ipilimumab blocks CTLA-4. There is no chemotherapy in this regimen. The FDA approved it for first-line unresectable pleural mesothelioma on October 2, 2020, on the basis of CheckMate-743.

Pembrolizumab plus pemetrexed and platinum. This is a single PD-1 checkpoint inhibitor (pembrolizumab) added to the chemotherapy backbone. The FDA approved it on September 17, 2024, on the basis of the IND.227 / KEYNOTE-483 trial.

The National Cancer Institute Mesothelioma Treatment summary lists both regimens, alongside platinum-pemetrexed (with or without bevacizumab), as accepted first-line options. No major guideline designates one immunotherapy regimen as preferred over the other. The oncology team makes the choice by weighing trial data against the patient’s histology, performance status, and contraindications.

CheckMate-743: What the Nivolumab+Ipilimumab Trial Showed

CheckMate-743 was a phase 3 open-label randomized trial of 605 patients with previously untreated unresectable pleural mesothelioma. Patients were randomized 1:1 to nivolumab plus ipilimumab for up to two years versus six cycles of pemetrexed plus cisplatin or carboplatin. The dual primary endpoints were overall survival in the intention-to-treat population and progression-free survival in the epithelioid histology subgroup.

The primary publication by Baas and colleagues appeared in The Lancet in February 2021. In the intention-to-treat population, median overall survival was 18.1 months with nivolumab plus ipilimumab versus 14.1 months with chemotherapy (HR 0.74; 95% CI 0.61 to 0.89; p=0.002). The 5-year update by Scherpereel and colleagues in the Journal of Clinical Oncology reports a 5-year overall survival rate of 14% with nivolumab plus ipilimumab versus 6% with chemotherapy, with no new safety signals.

For the closely related CheckMate-743 5-year survival data, the durability question matters. The trial was the first to show that some people with pleural mesothelioma can have multi-year disease control without continuous chemotherapy. The 14% absolute rate is also a reminder that the regimen is not a cure for most patients.

Treatment-related toxicity favored nivolumab plus ipilimumab. Grade 3 to 4 treatment-related adverse events occurred in 30% of patients on the immunotherapy arm versus 40% on chemotherapy, and 12% of immunotherapy patients discontinued treatment for toxicity versus 21% on chemotherapy. Immune-related adverse events, specific to checkpoint inhibition, occurred in roughly half of nivolumab-ipilimumab patients at any grade. They include endocrine effects, pneumonitis, colitis, and skin reactions, and most are managed with dose interruption and corticosteroids.

IND.227 / KEYNOTE-483: What the Pembrolizumab+Chemo Trial Showed

IND.227, also referenced as KEYNOTE-483, was a Canadian Cancer Trials Group-led phase 2/3 randomized trial led by Quincy Chu and colleagues. Patients with previously untreated advanced pleural mesothelioma were randomized to pembrolizumab plus pemetrexed-platinum versus pemetrexed-platinum chemotherapy alone.

The trial supported the September 17, 2024 FDA approval. Median overall survival was 17.3 months with pembrolizumab plus chemotherapy versus 16.1 months with chemotherapy alone (HR 0.79; 95% CI 0.64 to 0.98).

Two things are worth noting. The chemotherapy control arm in IND.227 (median OS 16.1 months) outperformed the chemotherapy arm in CheckMate-743 (14.1 months), so directly comparing immunotherapy-arm medians across the two trials is not valid. And while the absolute survival gain in IND.227 was smaller, the regimen keeps chemotherapy in the backbone, which oncology teams have the most operational experience delivering.

Histology Matters: The Sarcomatoid and Biphasic Question

The single most important histology-specific finding in the modern first-line literature comes from CheckMate-743. The benefit of nivolumab plus ipilimumab was substantially larger in patients with non-epithelioid (sarcomatoid or biphasic) histology than in those with epithelioid histology. From Baas and colleagues, Lancet 2021:

• Epithelioid subgroup (n=212 immunotherapy, n=196 chemotherapy): median OS 18.2 months versus 16.2 months. HR 0.85 (95% CI 0.66 to 1.10).
• Non-epithelioid subgroup (n=88 each arm): median OS 18.8 months versus 8.8 months. HR 0.46 (95% CI 0.30 to 0.70).

In sarcomatoid or biphasic disease, the chemotherapy median OS was under 9 months, and dual checkpoint blockade roughly doubled it. In epithelioid disease, the difference was smaller and did not reach statistical significance in the subgroup analysis.

For someone whose biopsy returns sarcomatoid or biphasic histology, CheckMate-743 provides the strongest randomized evidence for first-line immunotherapy without chemotherapy. For pure epithelioid disease, both nivolumab+ipilimumab and pembrolizumab+chemo are reasonable on the trial data, and the decision turns more on patient-specific factors. The pembrolizumab+chemo regimen is FDA-approved across histologies; histology-stratified survival from IND.227 is awaited in updated peer-reviewed publication.

Performance Status and Other Patient-Specific Factors

Both pivotal trials enrolled adults with ECOG performance status 0 or 1. ECOG 0 means fully active; ECOG 1 means restricted in strenuous activity but ambulatory and able to carry out light work. Patients with ECOG 2 or worse were not eligible, so the published survival numbers do not directly apply to people with poorer performance status at diagnosis.

Both trials excluded patients with active autoimmune disease requiring systemic immunosuppression, untreated central nervous system metastases, and interstitial lung disease. A person with significant inflammatory bowel disease, lupus, or rheumatoid arthritis on biologic therapy may not be a candidate for either immunotherapy regimen, and the decision shifts toward platinum-pemetrexed chemotherapy with or without bevacizumab.

Other factors the oncology team will weigh:

• Age and frailty. Cisplatin requires adequate renal function. Carboplatin substitution is an established option when cisplatin is not appropriate.
• History of immune-related conditions. Prior pneumonitis, autoimmune endocrine disease, or active dermatologic conditions raise checkpoint inhibitor risk.
• Tumor burden and symptom acuity. Heavy effusion burden and rapid symptom progression may be assessed differently from stable disease.
• Logistics. Nivolumab plus ipilimumab is given on its own schedule for up to two years. Pembrolizumab plus chemotherapy combines checkpoint dosing with the chemotherapy infusion cycle, then pembrolizumab continuation.

Bevacizumab plus pemetrexed and cisplatin remains a separate accepted first-line option, established by the MAPS trial (Zalcman et al., Lancet 2016), with median OS of 18.8 months versus 16.1 months without bevacizumab (HR 0.77; 95% CI 0.62 to 0.95). For patients in whom checkpoint inhibitors are contraindicated, this triplet is the most-supported chemotherapy-only option.

Practical Questions to Ask Your Oncology Team

The treatment decision for unresectable pleural mesothelioma in 2026 is genuinely a choice. The trial evidence supports more than one path, and the most useful thing the oncology team can do is make the reasoning behind a specific recommendation visible.

For broader context, see our mesothelioma treatment landscape 2026 overview. Reviewer Dr. Hedy Kindler directs the Multidisciplinary Mesothelioma Program at the University of Chicago and has written and spoken extensively on first-line systemic therapy. For background on what brings people to the diagnostic workup, see our early warning signs and latency guide.

Frequently Asked Questions